Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 5/20 | 0.41 |
| ▸ | WNT1 | P04628 | 6/20 | 0.40 |
| ▸ | GSK3B | P49841 | 6/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | PRKCB | P05771 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR1F | P30939 | 1/20 | 0.39 |
| ▸ | PAK4 | O96013 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454773 | 0.87 | FLT3 (0.46) | FLT3MAPK14PRKCBKITPAK4 | |
| SCHEMBL5451386 | 0.86 | FLT3 (0.43) | FLT3KDRPRKCBKITNPC1 | |
| SCHEMBL5448086 | 0.86 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2DGAT1CYP3A4 | |
| SCHEMBL5452844 | 0.84 | HTR1F (0.43) | FLT3MAPK14HTR1AHTR1FACACB | |
| SCHEMBL5457234 | 0.84 | MAPK14 (0.39) | FLT3WNT1GSK3BDYRK1AMAPK14 | |
| SCHEMBL5451964 | 0.83 | POLB (0.41) | PRKCBNPC1RAB9ASMN1; SMN2DGAT1 | |
| SCHEMBL5449453 | 0.82 | NPC1 (0.43) | FLT3PRKCBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5459485 | 0.81 | IDH1 (0.43) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5449478 | 0.81 | DGAT1 (0.45) | PRKCBNPC1RAB9ASMN1; SMN2DGAT1 | |
| SCHEMBL5448161 | 0.80 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2DGAT1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-02-15 | — | — | US | claimed |
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-02-15 | — | — | US | disclosed |
| EP-1608364-A1 | BICYCLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004080457-A1 | BICYCLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K15, MAP3K7, MAP3K19 | FLT3 720/4885WNT1 2835/4885GSK3B 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.